KR20120133134A - Composition for Prevention or Treatment of Dental Caries Comprising Extract of Tetrapanax papyriferus - Google Patents
Composition for Prevention or Treatment of Dental Caries Comprising Extract of Tetrapanax papyriferus Download PDFInfo
- Publication number
- KR20120133134A KR20120133134A KR1020110051654A KR20110051654A KR20120133134A KR 20120133134 A KR20120133134 A KR 20120133134A KR 1020110051654 A KR1020110051654 A KR 1020110051654A KR 20110051654 A KR20110051654 A KR 20110051654A KR 20120133134 A KR20120133134 A KR 20120133134A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- dental caries
- oral
- tongcho
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 90
- 208000002925 dental caries Diseases 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 230000002265 prevention Effects 0.000 title claims description 14
- 244000290970 Tetrapanax papyrifer Species 0.000 title abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000003960 organic solvent Substances 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940034610 toothpaste Drugs 0.000 claims abstract description 7
- 239000000606 toothpaste Substances 0.000 claims abstract description 7
- 210000000214 mouth Anatomy 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 235000013402 health food Nutrition 0.000 claims description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 5
- 239000002324 mouth wash Substances 0.000 claims description 4
- 229940051866 mouthwash Drugs 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- -1 oral cleanser Substances 0.000 abstract description 15
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 14
- 230000036541 health Effects 0.000 abstract description 13
- 102000000340 Glucosyltransferases Human genes 0.000 abstract description 9
- 108010055629 Glucosyltransferases Proteins 0.000 abstract description 9
- 235000013376 functional food Nutrition 0.000 abstract 1
- 229940041678 oral spray Drugs 0.000 abstract 1
- 239000000668 oral spray Substances 0.000 abstract 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 36
- 241000208125 Nicotiana Species 0.000 description 28
- 238000004519 manufacturing process Methods 0.000 description 22
- 229920001503 Glucan Polymers 0.000 description 16
- 239000002038 ethyl acetate fraction Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 150000002989 phenols Chemical class 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 244000061176 Nicotiana tabacum Species 0.000 description 8
- 241000194019 Streptococcus mutans Species 0.000 description 8
- 230000000845 anti-microbial effect Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 239000000469 ethanolic extract Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 239000002034 butanolic fraction Substances 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000009036 growth inhibition Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 240000003768 Solanum lycopersicum Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 231100000676 disease causative agent Toxicity 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 239000012676 herbal extract Substances 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 231100000820 toxicity test Toxicity 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 208000002064 Dental Plaque Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- 244000246386 Mentha pulegium Species 0.000 description 3
- 235000016257 Mentha pulegium Nutrition 0.000 description 3
- 235000004357 Mentha x piperita Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 235000014171 carbonated beverage Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000013882 gravy Nutrition 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 235000001050 hortel pimenta Nutrition 0.000 description 3
- 235000008960 ketchup Nutrition 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 229940071089 sarcosinate Drugs 0.000 description 3
- 235000015067 sauces Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 244000247747 Coptis groenlandica Species 0.000 description 2
- 235000002991 Coptis groenlandica Nutrition 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000005770 Eugenol Substances 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 2
- 229940088601 alpha-terpineol Drugs 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960002217 eugenol Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 239000000057 synthetic resin Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-ZDGBYWQASA-N (2s,5r)-5-methyl-2-propan-2-ylcyclohexan-1-ol Chemical compound CC(C)[C@@H]1CC[C@@H](C)CC1O NOOLISFMXDJSKH-ZDGBYWQASA-N 0.000 description 1
- KRLBLPBPZSSIGH-CSKARUKUSA-N (6e)-3,7-dimethylnona-1,6-dien-3-ol Chemical compound CC\C(C)=C\CCC(C)(O)C=C KRLBLPBPZSSIGH-CSKARUKUSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical compound NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- SVIJYLPSHPPVQF-UHFFFAOYSA-N 2-[2,2-diaminoethyl(dodecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCN(CC(N)N)CC(O)=O SVIJYLPSHPPVQF-UHFFFAOYSA-N 0.000 description 1
- GMGBBMQOXFAWRS-UHFFFAOYSA-N 2-[2,2-diaminoethyl(tetradecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCCN(CC(N)N)CC(O)=O GMGBBMQOXFAWRS-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 244000265736 Nelumbo pentapetala Species 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241000193987 Streptococcus sobrinus Species 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229930007050 cineol Natural products 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910001506 inorganic fluoride Inorganic materials 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000007823 ocimene derivatives Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- KFHHGNBIPJDZPH-UHFFFAOYSA-D pentamagnesium [oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O KFHHGNBIPJDZPH-UHFFFAOYSA-D 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- AYALWAPMJLOALU-UHFFFAOYSA-M potassium fluorophosphonic acid fluoride Chemical class P(=O)(O)(O)F.[F-].[K+] AYALWAPMJLOALU-UHFFFAOYSA-M 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- URLJMZWTXZTZRR-UHFFFAOYSA-N sodium myristyl sulfate Chemical compound CCCCCCCCCCCCCCOS(O)(=O)=O URLJMZWTXZTZRR-UHFFFAOYSA-N 0.000 description 1
- 229950005425 sodium myristyl sulfate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- AYGJDUHQRFKLBG-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;dihydrate Chemical compound O.O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 AYGJDUHQRFKLBG-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 108010048778 sporamycin Proteins 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- YUOWTJMRMWQJDA-UHFFFAOYSA-J tin(iv) fluoride Chemical compound [F-].[F-].[F-].[F-].[Sn+4] YUOWTJMRMWQJDA-UHFFFAOYSA-J 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229960004175 xylazine hydrochloride Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/312—Foods, ingredients or supplements having a functional effect on health having an effect on dental health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Abstract
Description
본 발명은 치아우식증의 예방 또는 치료용 조성물에 관한 것으로서, 보다 상세하게는 통초의 추출물을 유효성분으로 함유하며, 치아우식증의 예방 및/또는 치료에 유용하게 사용될 수 있는 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating dental caries, and more particularly, to a composition containing the extract of the herb as an active ingredient, which can be usefully used for the prevention and / or treatment of dental caries.
치아우식증이란 치은연상 및 치은연하의 치면 세균막에 존재하는 미생물들에 의해 음식물 중의 탄수화물이 대사되어 국소적으로 생산된 유기산의 작용으로 인해 치아의 경조직이 파괴되는 질환으로, 그 예방 및 치료제의 개발은 우리나라뿐만 아니라 세계적인 관심사 중 하나이다. 치아우식증은 인간의 생명에는 직접적인 관계가 없지만, 음식물의 저작기능이 저하되므로 소화계통의 질병에 직간접으로 영향을 미친다. 치아우식증의 이환율은 특히 어린이에게 많은데, 5세 어린이의 85%에 이르고 있을 정도로 대부분의 사람들이 치아우식증으로 인한 고통을 경험했거나 경험하고 있다.Dental caries is a disease in which the hard tissues of teeth are destroyed by the action of organic acids produced by the metabolism of carbohydrates in food by microorganisms in the gingival and subgingival bacterial membranes. It is one of the global concerns as well as Korea. Dental caries does not have a direct relationship to human life, but since the chewing function of food decreases, it directly or indirectly affects diseases of the digestive system. The morbidity rate of dental caries is particularly high in children, with 85% of children aged 5 years having experienced or experiencing pain from dental caries.
치아우식증의 발생 원인은 다양하나, 일반적으로 구강 내에 상주하는 세균의 발효 작용에 의해 치아에 부착된 음식물 찌꺼기의 당분이나 전분 등의 탄수화물이 분해되어 생기는 젖산이 치아 경조직의 석회를 탈각시켜 치아우식증이 발생하게 된다. 이러한 치아우식증을 일으키는 병원성 미생물로는 여러 종들이 알려져 있지만, 특히 스트렙토코커스 뮤탄스(Streptococcus mutans), 스트렙토코커스 소브리누스(Streptococcus sobrinus) 등이 치아우식증 발생의 주된 병원체로 작용한다(비특허문헌 1). 스트렙토코커스 뮤탄스는 균체외 또는 균체 표층에 글루코실트랜스퍼라제(glucosyltransferase, GTase)라는 효소를 분비하여 음식물 내 수크로오스를 기질로 하여 글루코오스와 프럭토오스를 생성하고, 동시에 글루코오스의 중합체인 불용성 글루칸(insoluble glucan)을 치면에 형성하게 된다. 이 글루칸에 의해 구강 내 다른 미생물들이 치면에 부착함으로써 치면 세균막, 즉 치태(dental plaque)를 형성하게 된다. 이 치태 내에서 스트렙토코커스 뮤탄스균을 포함한 젖산균이 증식하여 프럭토오스를 탄소원으로 젖산을 생성하고, 부착성 글루칸에 젖산이 포집, 농축된다. 이렇게 농축된 고농도의 산은 치아의 구성성분인 인산칼슘 중 Ca2 +를 녹아내리게 하여 치아의 외막인 법랑질을 용해시킴으로서 치아우식증을 유발하게 되는 것이다(비특허문헌 2).Although there are many causes of dental caries, lactic acid, which is caused by the breakdown of carbohydrates such as sugar and starch of food residues attached to teeth by the fermentation of bacteria that resides in the oral cavity, desorbs the lime of the dental hard tissues. Will occur. Several species are known as pathogenic microorganisms that cause dental caries, but in particular Streptococcus mutans ), Streptococcus sobrinus ) and the like act as a major pathogen for the development of dental caries (Non-Patent Document 1). Streptococcus mutans secrete an enzyme called glucosyltransferase (GTase) to extracellular or cell surface to produce glucose and fructose based on sucrose in food, and at the same time insoluble glucan, a polymer of glucose ) Will form on the surface. This glucan causes other microorganisms in the oral cavity to adhere to the dental plaque, forming a dental plaque, or dental plaque. Within this plaque, lactic acid bacteria, including Streptococcus mutans bacteria, multiply to produce lactic acid as a carbon source, and lactic acid is collected and concentrated in adherent glucan. So a high concentration of a concentrated acid of the calcium phosphate composition of the tooth melts the Ca 2 + unloaded by causing it to be a dental caries sikimeuroseo dissolving the outer membrane of the enamel of the teeth (Non-Patent Document 2).
이러한 치아우식증을 억제하기 위해 사용되는 방법으로는 스포라마이신(sporamycin), 반코마이신(vancomycin), 클로로헥시딘(chlorhexidine) 등의 항생물질을 이용하는 방법, 유기 또는 무기 불소에 의한 병원성 세균의 억제 방법 등이 이용되고 있다(비특허문헌 3). 그러나, 항생물질을 계속 이용하면 미생물이 내성을 갖게 되거나, 설사, 구토 등의 부작용을 유발할 수 있는 단점이 있을 뿐만 아니라, 이러한 항생물질의 남용으로 인해 구강 내 상재하는 세균들의 생육이 저해되는 문제점이 있다. 따라서, 효과적이고 안정성이 있는 치아우식증의 예방 및 치료제의 개발이 절실히 요구되고 있다.Methods used to suppress such dental caries include methods using antibiotics such as sporamycin, vancomycin, and chlorohexidine, and methods of inhibiting pathogenic bacteria by organic or inorganic fluoride. Etc. are used (Non Patent Literature 3). However, if the antibiotics are used continuously, not only the microorganisms become resistant or cause side effects such as diarrhea and vomiting, but also the problem of inhibiting the growth of bacteria in the oral cavity due to the abuse of these antibiotics. have. Therefore, there is an urgent need for the development of effective and stable prevention and treatment of dental caries.
한편, 통초(通草, Tetrapanax papyriferus K.)는 두릅나무과의 통탈목(Tetrapanax papyriferus K. Koch)의 줄기를 말하는 것으로서, 생김새는 원주형으로 백색이고, 질은 가볍고 유연하며, 가운데가 비어 있고, 탄력성이 있어 꺾어지기 쉽다. 통초는 덩굴로 뻗으며 굵기가 손가락과 같고 마디마다 2-3개의 가지가 붙어 있다. 가지 끝에 5개의 잎이 달렸고 열매가 맺히는데, 작은 모과 비슷하다. 씨는 검고 속은 흰데 먹으면 단맛이 있기 때문에 이것을 연복자(燕覆子)라고도 한다. 음력 정월, 2월에 가지를 베어 그늘에서 말리며, 줄기에 가는 구멍이 있어 양쪽 끝이 다 통한다.On the other hand, Tongcho (通 草, Tetrapanax papyriferus K. ) refers to the stems of the tree (Tetrapanax papyriferus K. Koch), the appearance is columnar, white, the quality is light and flexible, hollow in the middle, elastic There is this and is easy to be broken. Tongcho extends into vines with the same thickness as fingers, with 2-3 branches per node. Five leaves hang at the end of the branch and bear fruit, similar to small hairs. The seed is black and the inside is white, but it is sweet because it is sweet. Lunar New Year, in February, the branches are dried in the shade, and there is a hole in the stem, which leads to both ends.
통초란 이름은 요도가 막혀서 소변을 시원하게 보지 못하고 수종(水腫)이 발생했을 때 이 약재를 사용하면 바로 소변이 통하기 때문에 붙여진 것이다. 통초는 냄새가 없고, 맛은 달고 담담하며, 성질은 약간 차다(甘淡微寒). 또한, 통초는 열을 내리고 소변량을 늘려 임질, 요도염, 방광염, 산후 유즙분비를 촉진한다. 또한, 본초학에 따르면, 통초는 다섯 가지 임병을 낫게 하고, 오줌을 잘 나가게 하며, 관격(關格)된 것을 풀어 주고, 수종(水腫)을 낫게 하며, 번열(煩熱)을 멎게 하고 9규(竅)를 잘 통하게 하는 작용을 한다. 현재 통초의 추출물이 인체 구강암 세포주에 대해 항암작용이 있음이 알려져 있고(비특허문헌 4), 혈당 강하를 위한 생약 조성물의 한 성분으로서 통초가 사용될 수 있다는 보고가 있으나(특허문헌 1 및 특허문헌 2), 통초를 치아우식증의 예방이나 치료에 사용할 수 있음을 보여주는 문헌은 보고된 바가 없다.Tongcho is named because the urethra is blocked because the urine does not look cool, and there are several species of water (水腫). Tongcho has no smell, taste is sweet, and it is slightly cold. In addition, Tongcho lowers the heat and increases the amount of urine to promote gonorrhea, urethritis, cystitis, postpartum milk secretion. In addition, according to the herbology, Tongcho heals five kinds of disease, urinates well, releases physiognomy, heals species, and improves heat, ) To work well. Currently, it is known that the extract of Tongcho has anticancer activity against human oral cancer cell lines (Non-Patent Document 4), and there are reports that Tongcho may be used as a component of the herbal composition for lowering blood sugar (Patent Document 1 and Patent Document 2). However, no literature has been reported that can be used to prevent or treat dental caries.
이에, 본 발명자들은 치아우식증의 예방이나 치료에 유용하게 사용될 수 있는 다양한 생약 추출물에 대해 연구한 결과, 통초의 추출물이 종래 보고된 바 없는 뛰어난 치아우식증 예방 또는 치료 효과를 보인다는 사실을 밝힘으로써 본 발명을 완성하였다.Accordingly, the present inventors have studied various herbal extracts that can be usefully used for the prevention or treatment of dental caries. As a result, the present inventors have shown that the extracts of the herbaceous plants exhibit excellent dental caries prevention or treatment effects that have not been reported before. The invention has been completed.
본 발명은 통초 추출물을 유효성분으로 함유하는 치아우식증의 예방 또는 치료용 조성물을 제공하는 것을 목적으로 한다.It is an object of the present invention to provide a composition for the prevention or treatment of dental caries, which contains the herb extract as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 통초 추출물을 유효성분으로 함유하는 치아우식증의 예방 또는 치료용 구강용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for the oral cavity for the prevention or treatment of dental caries comprising the extract as an active ingredient.
또한, 본 발명은 통초 추출물을 유효성분으로 함유하는 치아우식증의 예방 또는 완화용 건강식품을 제공한다.In addition, the present invention provides a health food for the prevention or alleviation of dental caries containing the herb extract as an active ingredient.
본 발명은 통초 추출물을 유효성분으로 함유하는 치아우식증의 예방 또는 치료용 구강용 조성물을 제공한다.The present invention provides a composition for the oral cavity for the prevention or treatment of dental caries containing the herb extract as an active ingredient.
상기 통초 추출물은 통초에 2?30배량, 바람직하게는 5?20배량의 추출용매를 가하여 추출하는 것이 바람직하다. 추출용매로는 물을 사용하는 것이 일반적이지만, 필요에 따라 물 이외에 다른 유기용매를 사용해도 무방하다. 사용될 수 있는 유기용매로는 C1 내지 C4의 저급 알코올, 바람직하게는 에탄올, 아세톤, 또는 이의 수용액 등을 들 수 있지만 이에 한정되는 것은 아니다. 본 발명에 있어서, 상기 "통초 추출물"은 상기 추출용매를 이용하여 제조된 통초 추출물뿐만 아니라, 상기 통초 추출물에 하나 이상의 "분획화 유기용매"를 추가로 가하여 추출한 분획물도 포괄하는 의미로 사용된다. 상기 분획화 유기용매로는 특별히 한정되는 것은 아니며, 통상의 유기용매가 제한없이 사용될 수 있다. 본 발명의 바람직한 구현예에서는 통초의 수추출물에 대해 에틸아세테이트 또는 부탄올 등의 유기용매를 분획화 유기용매로 사용하였다.The Tongcho extract is preferably extracted by adding an extraction solvent of 2 to 30 times, preferably 5 to 20 times, to the Tongcho. Although water is generally used as the extraction solvent, other organic solvents may be used in addition to water as necessary. Organic solvents that may be used include, but are not limited to, C 1 to C 4 lower alcohols, preferably ethanol, acetone, or aqueous solutions thereof. In the present invention, the "tobacco extract" is used to encompass not only the tobacco extract prepared using the extracting solvent, but also the fraction extracted by adding one or more "fractionated organic solvents" to the tobacco extract. The fractionated organic solvent is not particularly limited, and conventional organic solvents may be used without limitation. In a preferred embodiment of the present invention, an organic solvent such as ethyl acetate or butanol was used as the fractionated organic solvent with respect to the water extract of the herb.
본 발명의 통초 추출물을 함유하는 구강용 조성물은 치약류, 구강청정제 또는 구강용 스프레이드 등의 제형으로 제조하여 사용할 수 있으나, 이에 한정하는 것은 아니다. 본 발명의 구강용 조성물에 있어서, 상기 치약류는 연마제, 점결제, 보습제, 발포제, 감미료, 향미제 등의 성분을 하나 이상 포함할 수 있다. 상기 연마제로는 수산화알루미늄, 무수규산, 규산알루미늄, 제2인산칼슘, 제2수산화물 및 무수물, 제3인산칼슘, 탄산칼슘, 피로인산칼슘, 불용성 메타인산나트륨, 제3인산마그네슘, 탄산마그네슘, 황산칼슘, 폴리메타아크릴산메틸, 기타 합성수지 등에서 1종 또는 2종 이상을 전체 조성물의 약 20?90%의 양으로 배합하여 사용할 수 있다(페이스트 치약의 경우에는 20?60%가 된다). 상기 점결제로는 가라기닌, 각종 점증용 셀룰로오스 유도체, 잔탄검, 트라가칸트 검(Tragacanth gum) 등의 검류, 폴리비닐 알코올, 폴리아크릴산 나트륨, 폴리아크릴산/말레인산 공중합체, 카르복시비닐 폴리머 등의 합성 고분자 유도체 등의 유기계 점결제와 실리카, 라포나이트 등의 무기계 점결제에서 1종 또는 2종 이상을 전체 조성물의 약 0.3?5%의 양으로 배합하여 사용할 수 있다. 치약류 중 페이스트상과 액상 구강용 조성물에서는 그 제조시 보습제로 솔비톨, 글리세린, 에틸렌글리콜, 프로필렌 글리콜, 폴리에테르 글리콜, 폴리프로필렌 글리콜 등에서 1종 또는 2종 이상을 전체 조성물의 약 10?70%의 양으로 배합하여 사용할 수 있다.The composition for oral cavity containing the tobacco extract of the present invention may be prepared by using a formulation such as toothpaste, mouthwash or mouth spray, but is not limited thereto. In the composition for oral cavity of the present invention, the toothpaste may include one or more components such as abrasives, binders, moisturizers, foaming agents, sweeteners, flavoring agents and the like. Examples of the abrasive include aluminum hydroxide, silicic anhydride, aluminum silicate, dicalcium phosphate, dihydrate and anhydride, tricalcium phosphate, calcium carbonate, calcium pyrophosphate, insoluble sodium metaphosphate, magnesium triphosphate, magnesium carbonate, and sulfuric acid. One, two or more of calcium, polymethyl methacrylate, and other synthetic resins may be used in combination in an amount of about 20 to 90% of the total composition (20 to 60% for paste toothpaste). Examples of the binder include synthetic resins such as garginine, various thickening cellulose derivatives, xanthan gum, gums such as tragacanth gum, polyvinyl alcohol, sodium polyacrylate, polyacrylic acid / maleic acid copolymer, and carboxyvinyl polymer. In organic binders, such as a polymeric derivative, and inorganic binders, such as a silica and a laponite, 1 type, or 2 or more types can be mix | blended in the quantity of about 0.3-5% of the whole composition. Paste and liquid oral compositions in dentifrices include sorbitol, glycerin, ethylene glycol, propylene glycol, polyether glycol, and polypropylene glycol as moisturizing agents in the preparation of about 10-70% of the total composition. It can be used in combination.
한편, 본 발명의 통초 추출물을 함유하는 구강용 조성물에는 맨톨(Mentol), 아네톨(Anetol), 오이게놀(Eugenol), 리모넨(Limonene), 오시멘(Ocimene), n-도데실알코올(n-Dodecy Alcohol), 시트로네놀(Citronenol), 알파터피네올(α-Terpineol), 살리실메틸(Methyl salycilate), 메틸아세테이트(Methyl Acetate), 시트로네릴 아세테이트(Citronelyl Acetate), 시네올(Cineol), 리나롤(Linalool), 에틸리나롤(Ethyl Linalool), 바닐린(Vanillin), 티몰(Thymol), 스피아민트(Speamint)유, 세지(Sage)유, 로즈마리(Rosemary)유, 계피(Cinamon)유 등의 항료를 단독 또는 조합하여 전체 조성물의 0.1?10%, 바람직하게는 0.5?5%의 양으로 배합하여 사용할 수 있다. 또한, 사카린나트륨, 스테비오사이드, 아스파탐, D-자일로오스(D-Xylose) 등과 같은 감미제 등을 전체 조성물의 0?1%, 바람직하게는 0.01?0.5%의 양으로 배합하여 사용할 수 있다.On the other hand, the composition for oral cavity containing the herbal extract of the present invention is menthol (Mentol), anetol (Anetol), Eugenol (Eugenol), limonene (Limonene), Ocimene, n-dodecyl alcohol (n -Dodecy Alcohol, Citronenol, Alpha-Terpineol, α-Terpineol, Methyl salycilate, Methyl Acetate, Citroneryl Acetate, Cineol ), Linalol, Ethyl Linalool, Vanillin, Thymol, Spearamint Oil, Sage Oil, Rosemary Oil, Cinnamon Oil These and other pharmaceuticals may be used alone or in combination in an amount of 0.1 to 10%, preferably 0.5 to 5% of the total composition. In addition, sweeteners such as sodium saccharin, stevioside, aspartame, D-Xylose and the like can be used in combination in an amount of 0 to 1%, preferably 0.01 to 0.5% of the total composition.
또한, 본 발명의 구강용 조성물에는 트리클로산, 클로로 헥시딘, 벤제토늄클로라이드, 벤잘코늄클로라이드, 세틸피리듐 클로라이드과 같은 양이온성 살균제, 모노플루오로인산나트륨과 모노플루오로 인산칼륨 등과 같은 알칼리금속 모노플루오로 포스페이트와 불화나트륨, 불화제일주석 등의 불소화물, 트라넥삼산, 입실론 아미노 카프론산, 알루미늄 클로로 히드록실 알란토인, 디히드로 콜레스타놀, 클리틸리친산류, 글리세로 포스테이트, 염화나트륨, 수용성 무기인산 화합물, 아스코르빈산(나트륨), 초산 dl-a-토코페롤, 자일리톨, 염산피리독신, 폴리비닐 피롤리돈 등의 각종 효능 성분 중 1종 또는 2종 이상을 선택 배합하여 사용할 수 있다.In addition, the composition for oral cavity of the present invention includes alkali metal monofluoro, such as cationic fungicides such as triclosan, chlorohexidine, benzetonium chloride, benzalkonium chloride, cetylpyridium chloride, sodium monofluorophosphate and potassium monofluorophosphate Fluorides such as phosphate, sodium fluoride, and tin fluoride, tranexamic acid, epsilon amino capronic acid, aluminum chlorohydroxy allantoin, dihydrocholestanol, cletilychinates, glycerophosphates, sodium chloride, and water-soluble inorganic phosphate compounds And one or two or more of various efficacy components such as ascorbic acid (sodium), dl-a-tocopherol acetate, xylitol, pyridoxine hydrochloride and polyvinyl pyrrolidone can be used in combination.
또한, 본 발명의 구강용 조성물에서 발포 성분으로 사용하는 계면활성제로는 음이온성 계면활성제, 비이온성 계면활성제 및/또는 양이온성 계면활성제를 사용할 수 있다. 여기서, 음이온성 계면활성제로는 라우릴 황산나트륨, 미리스틸 황산나트륨 등의 알킬 황산나트륨, N-라우로일 사르코신산나트륨(Sodium N-Lauroyl sarcosinate), N-미리스틸 사르코신산나트륨(Sodium N-miristyl sarcosinate) 등의 N-아실 사르코신산나트륨(Sodium N-acyl sarcosinate) 등을 사용할 수 있고, 비이온성 계면활성제로는 슈가지방산 에스테르, 말토스 지방산 에스테르, 락토스 지방산 에스테르 등과 같은 당(糖)유래 지방산 에스테르, 폴리옥시에틸렌 경화 피마자유, 폴리옥시에틸렌고급알코올 에테르, 폴리옥시 에틸렌 폴리옥시 프로필렌 공중합체, 폴리옥시 에틸렌 폴리프로필렌 지방산 에스테르 등을 사용할 수 있다. 양이온성 계면활성제로는 N-라우릴 디 아미노에틸글리신, N-미리스틸 디아미노에틸글리신 등과 같은 N-알킬 디 아미노에틸글리신, N-알킬-N-카르복시메틸 암모늄 베타인, 2-알킬-1-히드록시에틸 이미다졸린 베타인 나트륨 등을 사용할 수 있다. 이 경우 발포 성분으로는 음이온성 계면활성제를 주로 사용하며 대표적인 것으로는 라우릴 황산나트륨과 같은 알킬황산 나트륨을 가장 널리 사용하고 있다. 또한 이들 계면활성제는 1종 단독 또는 2종 이상 혼합하여 사용하는 것이 바람직하며, 배합량은 통상 전체 조성물의 0.01?0.5%, 보다 바람직하게는 0.05?0.3%를 사용한다.In addition, anionic surfactants, nonionic surfactants and / or cationic surfactants may be used as the surfactant used in the composition for oral cavity of the present invention. Here, the anionic surfactants include sodium lauryl sulfate, sodium alkyl sulfates such as myristyl sulfate, sodium N-Lauroyl sarcosinate, sodium N-miristyl sarcosinate, and sodium N-miristyl sarcosinate. Sodium N-acyl sarcosinate and the like can be used, and non-ionic surfactants include sugar-derived fatty acid esters such as sugar fatty acid esters, maltose fatty acid esters, lactose fatty acid esters, and polyethers. Oxyethylene hardened castor oil, polyoxyethylene higher alcohol ether, polyoxy ethylene polyoxy propylene copolymer, polyoxy ethylene polypropylene fatty acid ester and the like can be used. Cationic surfactants include N-alkyl di aminoethylglycine, such as N-lauryl di aminoethylglycine, N-myristyl diaminoethylglycine, N-alkyl-N-carboxymethyl ammonium betaine, 2-alkyl-1 Hydroxyethyl imidazoline betaine sodium and the like can be used. In this case, the anionic surfactant is mainly used as the foaming component, and sodium alkyl sulfate such as sodium lauryl sulfate is most widely used. Moreover, it is preferable to use these surfactant individually by 1 type or in mixture of 2 or more types, and, as for a compounding quantity, 0.01-0.5%, More preferably, 0.05-0.3% of the whole composition is used normally.
상기 통초 추출물은 본 발명의 구강용 조성물 총 중량에 대하여 0.01 내지 50 중량%로 포함될 수 있으나, 그 함량은 활성 성분의 흡수도, 환자의 연령, 성별, 상태, 치아우식증의 정도 등에 따라 적절히 조절될 수 있다.The tobacco extract may be included in an amount of 0.01 to 50% by weight based on the total weight of the composition for oral cavity of the present invention, the content of which may be appropriately adjusted according to the absorption of the active ingredient, the age, sex, condition, degree of dental caries of the patient, etc. Can be.
본 발명의 한 구현예에 따르면, 통초 추출물은 치아우식증의 원인균에 대해 강한 항균 활성을 나타내며, 특히 통초 수추출물의 에틸아세테이트 분획물에서 강한 항치주균 활성을 나타낸다(표 1 참조). 또한, 디스크 확산법을 이용한 항균 활성 실험에서는 70% 에탄올 추출물에서 가시적인 저해환이 관찰되어 치아우식균의 생장을 강하게 억제함을 확인할 수 있다(도 1 참조).According to one embodiment of the present invention, the herb extract exhibits strong antibacterial activity against the causative agent of dental caries, and particularly, shows strong anti-fungal bacterium activity in the ethyl acetate fraction of the herb extract (see Table 1). In addition, in the antimicrobial activity experiment using the disk diffusion method, visible inhibition ring is observed in 70% ethanol extract, it can be confirmed that strongly inhibit the growth of dental caries (see Fig. 1).
또한, 본 발명의 다른 구현예에 따르면, 치아우식균에 대한 항균 활성이 약했던 열수 추출물 처리군에서 글루칸 생성이 가장 강하게 억제되는 한편, 에틸아세테이트 및 부탄올 용매 분획물에서는 상기 열수 추출물의 약 절반 정도의 글루칸 생성 저해능을 나타내었고, 특히 치아우식균에 대한 항균 활성이 강하게 나타났던 에틸아세테이트 분획물의 경우 글루칸 생성 저해능이 비교적 낮게 나타나, 에틸아세테이트 분획물의 항균 활성은 글루코실트랜스퍼라제의 활성 억제보다는 직접적인 균생육 억제에 의해 나타난 것임을 추측할 수 있다(표 2 참조).In addition, according to another embodiment of the present invention, glucan production is most strongly inhibited in the hydrothermal extract treatment group in which the antibacterial activity against dental caries is weak, while in the ethyl acetate and butanol solvent fractions, about half of the glucan is extracted. In particular, ethyl acetate fraction showed a low inhibitory activity, especially in the ethyl acetate fraction which showed strong antibacterial activity against dental caries. The antibacterial activity of the ethyl acetate fraction showed a direct inhibition of bacterial growth rather than glucosyltransferase activity. It can be inferred that it is represented by (see Table 2).
또한, 본 발명의 다른 구현예에 따르면, 치아우식균에 처리시 확인된 항균 활성 정도와 유사하게 에틸아세테이트 분획물에서 페놀성 화합물의 함량이 가장 높게 측정되었으며, 부탄올 분획물에서도 다량의 페놀성 화합물이 존재함을 확인할 수 있는데, 이는 통초의 치아우식균에 대한 항균 활성이 통초에 존재하는 페놀성 화합물에 의한 것일 수 있음을 시사하고 있다(표 3 참조).In addition, according to another embodiment of the present invention, the content of the phenolic compound in the ethyl acetate fraction was determined to be the highest in the ethyl acetate fraction, similar to the degree of antimicrobial activity observed in dental caries, and a large amount of the phenolic compound was present in the butanol fraction. It can be confirmed, which suggests that the antibacterial activity against the dental caries of the herb may be due to the phenolic compound present in the herb (see Table 3).
또한, 본 발명의 다른 구현예에 따르면, 마우스를 이용한 독성 실험 결과, 실험에 사용된 모든 마우스에서 시험 물질 투여와 관련된 어떠한 임상 증상의 이상 소견도 관찰되지 않았고, 사망동물 또한 관찰되지 않았다(표 4 참조). 아울러. 실험동물 모두 유의적인 체중 감소 또는 증가 효과는 나타나지 않았다(표 5 참조).
In addition, according to another embodiment of the present invention, as a result of toxicity experiments using mice, no abnormal symptoms of any clinical symptoms related to administration of the test substance were observed in all mice used in the experiment, and no dead animals were also observed (Table 4 Reference). together. All experimental animals showed no significant weight loss or gain (see Table 5).
또한, 본 발명은 통초 추출물을 유효성분으로 함유하는 치아우식증의 예방 또는 완화용 건강식품을 제공한다.In addition, the present invention provides a health food for the prevention or alleviation of dental caries containing the herb extract as an active ingredient.
상기 통초 추출물은 치아우식증 증상의 예방이나 개선을 목적으로 건강식품에 첨가될 수 있으며, 통초 추출물을 식품 첨가물로 사용할 경우, 이를 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에는 통초 추출물이 원료에 대하여 30 중량% 이하, 바람직하게는 10 중량% 이하의 양으로 첨가된다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.The tobacco extract may be added to health foods for the purpose of preventing or improving dental caries symptoms, and when the tobacco extract is used as a food additive, it may be added as it is or used with other foods or food ingredients, Can be used accordingly. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). In general, in the preparation of food or beverages, the tobacco extract is added in an amount of 30% by weight or less, preferably 10% by weight or less based on the raw material. However, in the case of long-term consumption intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range .
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of the food to which the substance can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, teas, drinks, Alcoholic beverages and vitamin complexes, and the like and include all of the health foods in the conventional sense.
본 발명의 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물에는 포도당, 과당과 같은 모노사카라이드, 말토스, 수크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 솔비톨, 에리트리톨 등의 당알코올이 있다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 통초 추출물 100 ㎖ 당 일반적으로 약 0.01?0.04 g, 바람직하게는 약 0.02?0.03 g 이다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The above-mentioned natural carbohydrates include glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol, and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g, per 100 ml of tobacco extract.
상기 외에도 본 발명의 건강음료 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 통초 추출물은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만, 통초 추출물 100 중량부 당 0.01?0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the health beverage composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, Alcohol, a carbonation agent used for carbonated drinks, and the like. In addition, the tobacco extract may contain the flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The ratio of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of tobacco extract.
상기에서 살펴본 바와 같이, 상기 통초 추출물은 치아우식균에 대한 항균 효과가 우수하고, 치아우식균의 생육 및 균성장시 방출되는 효소인 글루코실트랜스퍼라제의 활성을 억제하며, 그 효과도 지속적일 뿐만 아니라, 천연물인 통초로부터 추출되어 매우 안전하므로, 치아우식증을 예방 및/또는 치료하기 위한 구강용 조성물 또는 건강식품으로 유용하게 사용될 수 있다.As described above, the tobacco extract has an excellent antibacterial effect on dental caries, inhibits the activity of glucosyltransferase, an enzyme released during the growth and growth of dental caries, and its effect is also persistent. In addition, since it is very safe to be extracted from natural vinegar, it can be usefully used as a composition for oral health or health food for preventing and / or treating dental caries.
도 1은 치아우식균에 대한 통초 추출물의 항균 활성을 보여주는 생육 저해환 실험 결과를 보여주는 사진으로서, (A)는 70% 에탄올 추출물 2 ㎎ 투여시 21 ㎜의 생육 저해환이 형성되었음을 나타내고, (B)는 열수 추출물 2 ㎎ 투여시 10 ㎜의 생육 저해환이 형성되었음을 나타낸다.1 is a photograph showing the growth inhibitory experimental results showing the antimicrobial activity of the tobacco extract against dental caries, (A) shows that growth inhibition ring of 21 mm was formed upon administration of 2 mg of 70% ethanol extract, (B) Shows that growth inhibition ring of 10 mm was formed upon administration of 2 mg of hydrothermal extract.
이하, 본 발명을 실시예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by way of examples.
단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명의 내용이 하기 실시예에 의해 한정되는 것은 아니다.
However, the following examples are only for illustrating the present invention, and the content of the present invention is not limited by the following examples.
실시예Example 1: One: 통초Head 추출물의 제조 Preparation of extract
<1-1> <1-1> 열수Heat number 추출물의 제조 Preparation of extract
건조된 통초 50 g에 증류수 1 리터를 첨가하여 3시간 동안 열수 추출한 후, 여과지를 사용하여 여과하여 동결건조시켰다.1 liter of distilled water was added to 50 g of dried tobacco, followed by extraction with hot water for 3 hours, followed by filtration and lyophilization using a filter paper.
<1-2> 유기용매 추출물의 제조<1-2> Preparation of organic solvent extract
건조된 통초 50 g에 70% 에탄올 0.5 리터를 첨가하여 1시간 동안 25℃에서 음파처리한 후, 여과지를 사용하여 여과하였고, 감압하에서 회전식 농축기를 이용하여 용매를 제거하였다.0.5 g of 70% ethanol was added to 50 g of dried tobacco, sonicated at 25 ° C. for 1 hour, filtered using filter paper, and the solvent was removed using a rotary concentrator under reduced pressure.
<1-3> <1-3> 열수Heat number 추출물의 활성 성분 Active ingredient of extract 분획물의Fraction 제조 Produce
실시예 <1-1>에서 제조한 통초의 열수 추출물을 물에 현탁한 후 용매의 극성도를 고려하여 에틸아세테이트 및 부탄올을 이용하여 극성이 낮은 용매에서 극성이 높은 용매로 순차적으로 계통 분획하여 각 유기용매 분획물을 얻었다. 획득한 유기용매 분획물을 감압 회전 농축기를 사용하여 농축한 후 25 ㎎/㎖ 농도로 DMSO (Dimetyl Sulfoxide)에 녹여 -20℃에 저장하였으며, 실험시 증류수에 희석하여 사용하였다.
After suspending the hot water extract of Tongcho prepared in Example <1-1> in water, and using ethyl acetate and butanol in consideration of the polarity of the solvent, the system fractionation from the low polar solvent to a high polar solvent sequentially An organic solvent fraction was obtained. The obtained organic solvent fractions were concentrated using a vacuum rotary concentrator, and then dissolved in DMSO (Dimetyl Sulfoxide) at a concentration of 25 mg / mL and stored at -20 ° C.
비교예Comparative example 1. One. 황련goldthread 추출물의 제조 Preparation of extract
통초 대신에 치아우식균에 대한 항균 활성이 보고된 바 있는 황련을 이용한 것을 제외하고는 실시예 <1-1>과 동일하게 하여 황련 수추출물을 제조하였다.
Except for using the antibacterial activity of the dental caries have been reported in place of the tobacco bark in the same manner as in Example <1-1> was prepared by extracting the water.
실험예Experimental Example 1. 치아우식증 원인균에 대한 성장 억제 활성 측정 1. Measurement of growth inhibitory activity against the causative agent of dental caries
본 실험에 사용한 치아우식증 원인균인 스트렙토코커스 뮤탄스 균주는 그람-양성의 통성 혐기성 세균으로서, 한국생명공학연구원 미생물자원센터로부터 분양받은 KCTC3065 균주를 BHI 브로스(Brain Heart Infusion broth)(Difco, USA)와 아가(Agar) 배지에 계대배양하여 실험에 사용하였다. 치아우식증 원인균에 대한 통초 추출물의 성장 억제 활성을 조사하기 위하여, 상기 스트렙토코커스 뮤탄스 균주를 BHI 브로스에 접종하여 계대배양한 후, 550 ㎚에서의 흡광도값이 0.1이 되도록 균액을 희석하였다. 이 희석액을 BHI 브로스에 10% 접종하고, 96-웰 마이크로플레이트에 200 ㎕씩 분주하였다. 분주 후, 최종 농도가 통초 70% 에탄올 추출물 및 열수 추출물은 1.25 ㎎/㎖, 열수 추출물 유래의 유기용매 분획물은 0.625 ㎎/㎖이 되도록 각각 웰에 첨가하였다. 20시간 동안 배양시킨 후 흡광도를 측정하여 생육억제능을 측정하였으며, 그 결과를 표 1에 나타내었다.The Streptococcus mutans strain, the causative agent of dental caries used in this experiment, is a Gram-positive and anaerobic bacterium. The KCTC3065 strain, which was distributed from the Korea Institute of Bioscience and Biotechnology, was isolated from BHI broth (Difco, USA) Subcultured in Agar medium was used for the experiment. In order to investigate the growth inhibitory activity of the tobacco extract against the causative agent of dental caries, the Streptococcus mutans strain was inoculated with BHI broth and passaged, and the bacterial solution was diluted so that the absorbance value at 550 nm was 0.1. This dilution was inoculated 10% in BHI broth and 200 μl aliquoted in 96-well microplates. After dispensing, the final concentration was added to the wells such that the total concentration of 70% ethanol extract and hot water extract was 1.25 mg / ml, and the organic solvent fraction derived from hot water extract was 0.625 mg / ml. After incubation for 20 hours, the absorbance was measured to measure growth inhibition, and the results are shown in Table 1.
(㎍/㎖)Treatment concentration
(Μg / ml)
추출물70% ethanol
extract
분획물Ethyl acetate
Fraction
성장 저해능(%)Dental caries
Growth inhibition (%)
표 1로부터 알 수 있는 바와 같이, 70% 에탄올 추출물에서 가장 강한 항균 활성을 확인하였다. 또한, 수추출물의 에틸아세테이트 분획물을 처리할 경우, 모액인 통초의 열수 추출물보다 2배 희석된 농도에서도 4배 정도 강한 항치주균 활성을 확인하여, 활성 성분이 용매 분획에 의해 농축되어 효율성이 높아진 것을 확인하였다.
As can be seen from Table 1, the strongest antimicrobial activity was confirmed in 70% ethanol extract. In addition, when the ethyl acetate fraction of the water extract was treated, anti-fungal bacterium activity was confirmed about 4 times stronger even at twice the dilution concentration than the hot water extract of the mother liquor Tongcho, and the active ingredient was concentrated by the solvent fraction to increase the efficiency. It was confirmed.
실험예Experimental Example 2. 치아우식증 원인균에 대한 항균 활성 측정 2. Determination of antimicrobial activity against bacteria causing dental caries
디스크 확산법에 의해 실시예 1에서 제조한 통초 추출물의 항균 활성을 측정하였다. 이를 위하여, 1.5% 아가를 첨가한 BHI 플레이트를 베이스층(base layer)으로, 또 OD550 ㎚에서 흡광도가 0.1이 되게 희석한 균액 10%를 1% 아가가 첨가된 BHI 배지에 접종한 것을 오버층(over layer)으로 준비한 후, 그 위에 70% 에탄올 추출물과 열수 추출물이 각각 2 ㎎ 처리된 8 ㎜ 종이 디스크를 올려 항균 활성에 의한 저해환의 크기를 측정하였다.The antimicrobial activity of the tobacco extract prepared in Example 1 was measured by the disk diffusion method. To this end, a BHI plate containing 1.5% agar was inoculated into a base layer, and 10% of the bacterial solution diluted to an absorbance of 0.1 at 550 nm in BOD medium containing 1% agar. After the preparation (over layer), the size of the inhibitory ring due to antimicrobial activity was measured by placing 8 mm paper disks treated with 2 mg of 70% ethanol extract and hot water extract.
그 결과, 일정 농도의 스트렙토코커스 뮤탄스 균주가 존재하는 배양 플레이트에 통초 추출물을 처리한 결과, 70% 에탄올 추출물에서 가시적인 저해환이 생성되어 치아우식균의 생장을 강하게 억제하고 있음을 확인하였다(도 1).
As a result, as a result of treatment of the tobacco extract to the culture plate containing a certain concentration of Streptococcus mutans strain, it was confirmed that visible inhibition ring is generated in 70% ethanol extract to strongly inhibit the growth of dental caries (FIG. One).
실험예Experimental Example 3. 3. 글루칸Glucan 생성 produce 저해능Low performance 측정 Measure
구강내 음식물 속의 수크로오스를 기질로 하여 치면에 불용성 글루칸을 형성하는 글루코실트랜스퍼라제의 특성을 이용하여, 치아우식균에 의해 분비되는 글루코실트랜스퍼라제를 수집한 후 수크로오스가 포함된 완충 용액과 통초 열수 추출물 및 그의 유기용매 분획물들을 첨가하여 글루칸 생성 저해능을 확인하였다. 먼저, 스트렙토코커스 뮤탄스 균주를 BHI 브로스에 접종하여 37℃ 배양기에서 24시간 배양한 후, 4℃에서 4,300 rpm으로 30분간 원심분리하여 상징액을 취하였다. 0.2 ㎛ 주사기형 필터로 상기 상징액을 여과한 후, Amicon Ultra Centrifugal Filter(MWCO 30 kDa, Cat. No. UFC903008, Millipore)를 사용하여 조효소액을 제조하였다.Using glucosyltransferase which forms insoluble glucan on the tooth surface by using sucrose in oral food as a substrate, glucosyltransferase secreted by dental caries is collected and buffer solution containing sucrose and whole hot water Extracts and their organic solvent fractions were added to confirm glucan production inhibition. First, Streptococcus mutans strains were inoculated in BHI broth and incubated in a 37 ° C. incubator for 24 hours, followed by centrifugation at 4,300 rpm for 30 minutes to obtain supernatant. After filtering the supernatant with a 0.2 μm syringe-type filter, a crude enzyme solution was prepared using an Amicon Ultra Centrifugal Filter (MWCO 30 kDa, Cat. No. UFC903008, Millipore).
글루코실트랜스퍼라제의 활성은 수크로오스를 기질로 하여 생성된 불용성 글루칸의 농도를 분광광도계를 이용하여 측정함으로써 확인하였다. 이를 위하여, 유리 시험관에 기질 용액(0.0625 M Potassium Phosphate Buffer (pH 6.5) 1 리터 중 Sucrose 12.5 g, NaN3 0.25 g 함유) 800 ㎕, 조효소액 20 ㎕ 및 통초 열수 추출물 또는 용매 분획물 또는 황련 추출물 180 ㎕를 첨가하여 최종 용량이 1 ㎖가 되도록 하였다. 음성대조군으로는 증류수 180 ㎕를 첨가하였다. 시험관을 30° 정도 경사지게 하여 37℃ 배양기에서 30시간 반응시켰다. 반응 후 원심분리하여 상징액을 버리고 4 ㎖의 증류수를 가하여 10분간 초음파 처리하여 형성되어 있는 글루칸을 분산시켰다. 분산 직후 분광광도계로 550 ㎚에서 흡광도를 측정하였고, 각 시료의 글루코실트랜스퍼라제에 대한 저해율을 하기 식에 의해 계산하였으며, 그 결과를 표 2에 나타내었다.The activity of glucosyltransferase was confirmed by measuring the concentration of insoluble glucan produced using sucrose as a substrate using a spectrophotometer. For this purpose, 800 μl of substrate solution (containing 12.5 g of Sucrose, 0.25 g of NaN 3 in 1 liter of 0.0625 M Potassium Phosphate Buffer (pH 6.5)), 20 μl of coenzyme solution and 180 μl of hot water extract or solvent fraction or rhubarb extract Was added to bring the final volume to 1 ml. As a negative control, 180 μl of distilled water was added. The test tube was inclined at about 30 ° and allowed to react for 30 hours in a 37 ° C incubator. After the reaction, the supernatant was discarded by centrifugation, and 4 ml of distilled water was added to sonicate for 10 minutes to disperse the formed glucan. The absorbance was measured at 550 nm with a spectrophotometer immediately after dispersion, and the inhibition rate for glucosyltransferase of each sample was calculated by the following formula, and the results are shown in Table 2.
글루칸 생성 저해율(%) = [{(control - control blank) - (sample - sample blank)}/(control - control blank)] × 100% Inhibition of glucan production = [{(control-control blank)-(sample-sample blank)} / (control-control blank)] × 100
(㎍/㎖)Treatment concentration
(Μg / ml)
분획물Ethyl acetate
Fraction
분획물Butanol
Fraction
열수 추출물goldthread
Hydrothermal extract
저해율(%)Glucan generation
Inhibition rate (%)
표 2로부터 알 수 있는 바와 같이, 치아우식균에 대한 항균 활성이 약했던 열수 추출물 처리군에서 글루칸 생성이 가장 강하게 억제되었다. 반면, 두 용매 분획물에서는 약 20% 정도의 글루칸 생성 저해능을 확인하였으며, 특히 치아우식균에 대한 항균 활성이 강하게 나타났던 에틸아세테이트 분획물의 경우 글루칸 생성 저해능이 비교적 낮게 나타나 에틸아세테이트 분획물의 항균 활성은 글루코실트랜스퍼라제 활성 억제보다는 직접적인 균생육 억제에 의해 나타난 것임을 추측할 수 있었다. 아울러, 치아우식균에 대한 항균 활성이 보고된 황련 열수 추출물을 동량 처리한 후 활성을 비교한 결과, 상기 통초 추출물과 황련 추출물은 유사한 글루칸 생성 저해율을 보이는 것으로 확인되었다.
As can be seen from Table 2, the glucan production was most strongly inhibited in the hydrothermal extract treatment group in which the antibacterial activity against dental caries was weak. On the other hand, the two solvent fractions showed about 20% inhibition of glucan production. In particular, the ethyl acetate fraction, which exhibited strong antibacterial activity against dental caries, exhibited relatively low inhibition of glucan production. It could be inferred that this was indicated by direct fungal growth inhibition rather than siltransase activity inhibition. In addition, as a result of comparing the activity after the same amount of the antibacterial activity against the dental caries, which was reported the antibacterial activity, it was confirmed that the tobacco extract and the extract of the yellow lotus showed similar inhibition rate of glucan production.
실험예Experimental Example 4. 총 페놀성 화합물의 함량 측정 4. Determination of total phenolic compound content
종래에 치아우식증 억제 활성이 있는 것으로 알려진 생약재들에서 페놀성 화합물의 함량이 높다는 점이 보고된 바 있으므로(Lee HO, et al., Antibacterial effects of sophora flavescens on Streptococcus mutans. Korea J. Food Nutr. 13: 536-546, 2000; Yun-Mi Park, et al., J. Korean Soc. Food Sci. Nutr. 35(3):284-293, 2006), 이를 근거로 통초의 열수 추출물 및 열수 추출물 유래 유기용매 분획물 내의 총 페놀성 화합물의 함량을 Folin-Denis법(Slater TF. 1984. Free radical mechanisms in tissue injury. Biochem J 222:1-15)을 이용하여 측정하였다. 통초의 열수 추출물과 두 종류의 용매 분획물을 증류수로 10배 희석하여 2 ㎖씩 취한 후, 2배 희석한 Folin-Ciocalteu' 시약(Sigma, MO, USA)을 동량 첨가하여 3분간 반응시켰다. 그 후 동량의 10% Na2CO3를 서서히 가한 후 1시간 동안 반응시켰고, 분광광도계(UV/Vis Spectrophotometer U-2900, HITACHI, Tokyo, Japan)를 이용하여 700 ㎚에서 흡광도를 측정하였다. 측정한 흡광도로부터 탄닌산을 이용한 표준곡선으로 총 페놀성 화합물의 양을 환산하였으며, 그 결과를 표 3에 나타내었다.It has been reported that the content of phenolic compounds is high in herbal medicines known to have inhibitory activity against dental caries (Lee HO, et al., Antibacterial effects of sophora flavescens on Streptococcus mutans.Korea J. Food Nutr. 13: 536-546, 2000; Yun-Mi Park, et al., J. Korean Soc.Food Sci.Nutr. 35 (3): 284-293, 2006), based on this The content of total phenolic compounds in the fractions was determined using the Folin-Denis method (Slater TF. 1984. Free radical mechanisms in tissue injury. Biochem J 222: 1-15). The hot water extract and the two kinds of solvent fractions were diluted 10 times with distilled water, and each of 2 ml was taken. The same amount of 2 times diluted Folin-Ciocalteu 'reagent (Sigma, MO, USA) was added and reacted for 3 minutes. Thereafter, the same amount of 10% Na 2 CO 3 was slowly added and reacted for 1 hour, and the absorbance was measured at 700 nm using a spectrophotometer (UV / Vis Spectrophotometer U-2900, HITACHI, Tokyo, Japan). From the measured absorbance, the total amount of the phenolic compound was converted into a standard curve using tannic acid, and the results are shown in Table 3.
표 3으로부터 알 수 있는 바와 같이, 치아우식균에 처리시 확인된 항균 활성 정도와 유사하게 에틸아세테이트 분획물에서 페놀성 화합물의 함량이 가장 높게 측정되었으며, 부탄올 분획물에서도 다량의 페놀성 화합물이 존재함을 확인하였다. 이는 통초의 치아우식균에 대한 항균 활성이 통초에 존재하는 페놀성 화합물에 의한 것일 수 있음을 시사한다.
As can be seen from Table 3, the content of phenolic compounds in the ethyl acetate fraction was measured to be the highest in the ethyl acetate fraction, similar to the degree of antibacterial activity observed in dental caries, and the large amount of phenolic compounds were also present in the butanol fraction. Confirmed. This suggests that the antimicrobial activity of Tobacco on dental caries may be due to the phenolic compounds present in Tobacco.
실험예Experimental Example 5. 5. 급성독성Acute toxicity 실험 Experiment
통초 추출물의 안전성에 대한 자료를 마련하기 위하여 단회투여 독성실험을 수행하였다. 단회투여 독성 실험은 식품의약품안전청 고시 제2005-60호 의약품 등의 독성시험방법의 "비임상시험 관리기준"(2005년 10월 25일)에 따라 암?수 ICR 마우스를 이용하여 수행하였다. 동물구입 후 약 1주일 동안 온도 23±3℃, 상대습도 50±10%, 환기횟수 시간당 12?16회, 조명 12시간 명암주기(점등 7:00, 소등 19:00), 조도 150?300 Lx인 사육 환경하에서 검역 및 순화시키면서 외관을 육안으로 검사한 후 건강한 동물을 골라 실험에 사용하였다. 암수 각각의 마우스를 각 군당 5마리씩 설정하여, 케이지에 5마리씩 개별 수용하였다. 사료와 물은 자유섭취 시켰으며, 사료는 실험동물용 고형사료(PMI nutrition, USA)를 공급하였다.A single dose toxicity test was performed to prepare data on the safety of the tobacco extract. Single-dose toxicity experiments were performed using male and female ICR mice according to the "Non-clinical Trial Management Standards" (October 25, 2005) of Toxicology Test Methods, such as Food and Drug Administration Notification No. 2005-60. About 1 week after purchase, temperature 23 ± 3 ℃, relative humidity 50 ± 10%, ventilation frequency 12 ~ 16 times per hour, lighting 12 hours light cycle (light up 7:00, light off 19:00), illumination 150 ~ 300 Lx The animals were visually inspected while being quarantined and purified under a human breeding environment, and healthy animals were selected for the experiment. Male and female mice were set up in 5 groups in each group, and 5 were individually housed in cages. Feed and water were freely ingested, and the feed was fed solid animal feed (PMI nutrition, USA) for laboratory animals.
통초 열수 추출물의 투여 용량은 2,500 ㎎/㎏ 및 1,250 ㎎/㎏(Mouse, B.W.)의 2가지 용량으로 설정하였으며, 부형제인 생리식염수로 각각의 투여 용량별로 희석하여 시험에 사용하였다. 투여 경로는 경구투여법을 이용하였으며, 동물을 하룻밤 절식시킨 후 경구투여용 일회용 존데와 주사관을 이용하여 배부 피부 고정법으로 몸체를 고정한 후 경구 투여하였다.Two doses of Thucho hot-water extract were set at 2,500 mg / kg and 1,250 mg / kg (Mouse, B.W.), and each of them was diluted in each dose with an excipient physiological saline and used for the test. The route of administration was administered by oral administration. After fasting the animals overnight, the body was fixed by the dorsal skin fixation method using oral administration disposable sonde and injection tube and then orally administered.
임상 증상은 투여 직후부터 6시간 동안 매시간 관찰하였으며, 그 후 14일 동안 1일 1회, 일반 상태의 변화, 운동성, 외관, 자율신경 등의 일반증상 및 사망례를 관찰하였다. 체중은 입수 시, 군 분리전 및 시험물질 투여 후 1, 3, 7, 14일에 각각 측정하였다. 실험동물을 희생하기 전날 밤 18시간 절식 시킨 후 Zoletil 50( Virbac S.A, France)과 자일라진 히드로클로라이드(Xylazine Hydrochloride, 바이엘 코리아 주식회사, 경기도)를 복강 내 주사하여 마취하였으며, 후대정맥을 통한 방혈을 실시한 후 모든 장기에 대한 육안적 병변을 관찰하였다.Clinical symptoms were observed every hour for 6 hours immediately after administration, and then general symptoms such as changes in general condition, motility, appearance, autonomic nerve, and death were observed once daily for 14 days. Body weights were measured at day 1, 3, 7, 14 after group separation and at the time of administration of test substance, respectively. After 18 hours of fasting the night before the sacrifice, the animals were anesthetized by intraperitoneal injection of Zoletil 50 (Virbac SA, France) and xylazine hydrochloride (Bayer Korea Co., Ltd., Gyeonggi-do). Afterwards, gross lesions on all organs were observed.
그 결과, 실험에 사용된 모든 암?수 ICR 마우스에서 보행 장애, 행동 이상, 웅크림, 설사, 부종, 호흡 촉박, 몸단장, 뛰어오름, 유루, 무기력증, 구토, 비루, 마비, 유연 등 시험 물질 투여와 관련된 어떠한 임상 증상의 이상 소견도 관찰되지 않았고, 모든 암?수 ICR 마우스에서 사망동물도 관찰되지 않았다(표 4). 따라서, 통초 추출물은 한계용량(2,500 ㎎/㎏/day)까지 경구 투여하여도 사망을 관찰할 수 없어 LD50 값은 산출되지 않았다.As a result, all the male and female ICR mice used in the experiment were treated with test substance such as gait disorder, behavioral disorder, squat, diarrhea, swelling, tightness of breath, grooming, jumping, seizures, lethargy, vomiting, nasal secretion, paralysis, and softness. Abnormal findings of any relevant clinical symptoms were not observed and no deaths were observed in all male and female ICR mice (Table 4). Therefore, even if the Tobacco extract is administered orally up to the limit dose (2,500 mg / kg / day), death can not be observed LD 50 The value was not calculated.
(㎎/㎏)Volume
(Mg / kg)
또한, 통초 열수 추출물을 경구로 단회 투여한 후 1, 3, 7, 14일 동안 실험동물의 체중변화를 관찰한 결과, 대조군에 비교시 약간의 체중이 감소하였으며, 특히 암컷의 경우 1일과 3일에서 체중이 감소하는 경향이 나타났으나, 7일째부터 체중이 회복되었다. 실험동물 모두 유의적인 체중 감소 또는 증가 효과는 관찰되지 않았다(표 5).In addition, as a result of oral single-dose administration of the extract, the body weight of the experimental animals was observed for 1, 3, 7, and 14 days. Showed a tendency to lose weight at, but recovered from day 7. No significant weight loss or increase was observed in all experimental animals (Table 5).
(㎎/㎏)Volume
(Mg / kg)
(male)cock
(male)
(female)female
(female)
제조예Manufacturing example 1: One: 통초Head 추출물을 포함하는 구강용 조성물의 제조 Preparation of the composition for oral cavity containing the extract
<1-1> 치약의 제조<1-1> Preparation of Toothpaste
실시예 1의 통초 추출물 ?????????????????? 1 gHerb extract of Example 1 ?????????????????? 1 g
탄산수소나트륨?????????????????????? 20 gSodium bicarbonate ???????????????????????? 20 g
글리세린????????????????????????? 15 gglycerin????????????????????????? 15 g
화이트클레이 ??????????????????????? 2 gWhite Clay ??????????????????????? 2 g
죽염??????????????????????????? 10 gBamboo salt ??????????????????????????? 10 g
비타민 E ????????????????????????? 2 gVitamin E ????????????????????????? 2 g
정제수 점도에 맞게 소량Small amount to match the purified water viscosity
상기한 원료를 배합하여 치아우식증 예방 효과를 지닌 천연 치약을 제조하였다. 청량감을 주기 위해 멘톨이나 페퍼민트 정유를 첨가할 수도 있다.By combining the above raw materials to prepare a natural toothpaste having a dental caries prevention effect. You can also add menthol or peppermint essential oils for a refreshing feel.
<1-2> 구강청정제의 제조<1-2> Preparation of Oral Cleaning Agent
실시예 1의 통초 추출물 ?????????????????? 0.5%Herb extract of Example 1 ?????????????????? 0.5%
에탄올??????????????????????????? 15%ethanol??????????????????????????? 15%
글리세린?????????????????????????? 10%glycerin?????????????????????????? 10%
나트륨 벤조에이트 ???????????????????? 0.15%Sodium benzoate ???????????????????? 0.15%
삭카린 나트륨??????????????????????? 0.1%Zalcarin Sodium ??????????????????????? 0.1%
페퍼민트 정유 ?????????????????????? 0.15%Peppermint Refinery ?????????????????????? 0.15%
정제수(이온교환수) ??????????????????? 74.09%Purified Water (Ion Exchange Water) ??????????????????? 74.09%
pH 6.0pH 6.0
일반적인 구강청정제 성분인 알코올, 습윤제, 계면활성제로 에탄올, 글리세린, 나트륨벤조에이트를 사용하고, 실시예 1에서 제조한 통초 추출물을 첨가하여 치아우식증 및 구취 예방효과를 지닌 구강청정제를 제조하였다. 청량감을 더하기 위해 페퍼민트 정유를 첨가할 수 있으며, 한약재 추출물에 의한 맛을 조정하기 위해 삭카린 나트륨을 첨가할 수 있다.
Alcohol, humectant, surfactant, ethanol, glycerin, sodium benzoate are used as a general mouthwash component, and the herbal extract prepared in Example 1 was added to prepare a mouthwash having an effect of preventing dental caries and bad breath. Peppermint essential oil can be added to add a refreshing feeling, and saccharin sodium can be added to adjust the taste by the herbal extract.
제조예Manufacturing example 2: 2: 통초Head 추출물을 함유하는 건강식품의 제조 Preparation of Health Foods Containing Extract
<2-1> 식품의 제조<2-1> Manufacturing of food
실시예 1에서 제조한 통초 추출물을 포함하는 식품을 다음과 같이 제조하였다.The food containing the tobacco extract prepared in Example 1 was prepared as follows.
1. 조리용 양념의 제조1. Preparation of cooking seasoning
통초 추출물 20?95 중량%로 건강 증진용 조리용 양념을 제조하였다.A health promotion cooking seasoning was prepared with 20-95% by weight of Tongcho extract.
2. 토마토 케찹 및 소스의 제조2. Manufacture of tomato ketchup and sauce
통초 추출물 0.2?1.0 중량%를 토마토 케찹 또는 소스에 첨가하여 건강 증진용 토마토 케찹 또는 소스를 제조하였다.Health-promoting tomato ketchup or sauce was prepared by adding 0.2-1.0% by weight of the tobacco extract to tomato ketchup or sauce.
3. 밀가루 식품의 제조3. Manufacture of flour food
통초 추출물 0.5?5.0 중량%를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.Tobacco extract 0.5-5.0% by weight was added to the flour, using this mixture to prepare bread, cakes, cookies, crackers and noodles to produce health foods.
4. 스프 및 육즙(gravies)의 제조4. Manufacture of soups and gravies
통초 추출물 0.1?5.0 중량%를 스프 및 육즙에 첨가하여 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.Tonic extract 0.1-5.0% by weight was added to soups and gravy to prepare health products, noodle soup and gravy.
5. 그라운드 비프(ground beef)의 제조5. Manufacture of ground beef
통초 추출물 10 중량%를 그라운드 비프에 첨가하여 건강 증진용 그라운드 비프를 제조하였다.10% by weight of the tobacco extract was added to the ground beef to prepare a ground beef for health promotion.
6. 유제품(dairy products)의 제조6. Manufacture of dairy products
통초 추출물 5?10 중량%를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.5-10% by weight of Tobacco extract was added to milk, and the milk was used to prepare various dairy products such as butter and ice cream.
7. 선식의 제조7. Manufacturing of wires
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다. 검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다. 통초 추출물을 진공 농축기에서 감압?농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다. 상기에서 제조한 곡물류, 종실류 및 통초 추출물의 건조분말을 다음의 비율로 배합하여 제조하였다.Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh. Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer. The extract was concentrated under reduced pressure in a vacuum concentrator, dried by spraying and a hot air dryer, and ground to a particle size of 60 mesh using a grinder to obtain a dry powder. It was prepared by combining the dry powder of the grains, seeds and tobacco extract prepared in the following ratio.
곡물류(현미 30 중량%, 율무 15 중량%, 보리 20 중량%),Cereals (30% by weight of brown rice, 15% by weight of yulmu, 20% by weight of barley)
종실류(들깨 7 중량%, 검정콩 8 중량%, 검정깨 7 중량%),Seeds (7% by weight perilla, 8% by weight black bean, 7% by weight black sesame)
통초 추출물의 건조 분말(3 중량%),Dry powder (3% by weight) of the soybean extract,
영지(0.5 중량%),(0.5% by weight),
지황(0.5 중량%)(0.5% by weight)
<2-2> 음료의 제조<2-2> Production of beverage
1. 탄산음료의 제조1. Manufacture of carbonated beverages
통초 추출물 1?5%, 설탕 5?10%, 구연산 0.05?0.3%, 카라멜 0.005?0.02%, 비타민 C 0.1?1%의 첨가물을 혼합하고, 여기에 79?94%의 정제수를 섞어서 시럽을 만들고, 상기 시럽을 85?98℃에서 20?180초간 살균하여 냉각수와 1:4의 비율로 혼합한 다음 탄산가스를 0.5?0.82%를 주입하여 통초 추출물을 함유하는 탄산음료를 제조하였다.Add 1 ~ 5% of Tobacco Extract, 5 ~ 10% Sugar, 0.05 ~ 0.3% Citric Acid, 0.005 ~ 0.02% Caramel, 0.1 ~ 1% Vitamin C, and mix it with 79 ~ 94% Purified Water to make syrup. , The syrup was sterilized at 85-98 ° C. for 20-180 seconds, mixed with cooling water at a ratio of 1: 4, and 0.5-0.82% of carbon dioxide was injected to prepare a carbonated beverage containing a tobacco extract.
2. 건강음료의 제조2. Manufacture of health drinks
액상과당(0.5%), 올리고당(2%), 설탕(2%), 식염(0.5%), 물(75%)과 같은 부재료와 통초 추출물(3%)을 균질하게 배합하여 순간 살균을 한 후 이를 유리병, 페트병 등 소포장 용기에 포장하여 건강음료를 제조하였다.Instant sterilization by homogeneously mixing subsidiary ingredients such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%), water (75%), and tobacco extract (3%) This was packaged in small packaging containers such as glass bottles and PET bottles to prepare a healthy beverage.
3. 야채주스의 제조3. Manufacture of vegetable juice
통초 추출물 5 g을 토마토 또는 당근주스 1,000 ㎖에 가하여 건강 증진용 야채주스를 제조하였다.Tobacco extract 5 g was added to 1,000 ml of tomato or carrot juice to prepare vegetable juice for health promotion.
4. 과일주스의 제조4. Manufacture of fruit juice
통초 추출물 1 g을 사과 또는 포도주스 1,000 ㎖에 가하여 건강 증진용 과일주스를 제조하였다.1 g of tobacco extract was added to 1,000 ml of apple or grape juice to prepare fruit juice for health promotion.
Claims (11)
통초 추출물은 통초에 2?30배량의 추출용매를 가하여 추출되는 구강용 조성물.The method according to claim 1,
Tongcho extract is a composition for oral cavity extracted by adding 2 ~ 30 times the amount of the extraction solvent to Tongcho.
상기 추출용매는 물 또는 유기용매인 구강용 조성물.The method according to claim 2,
The extraction solvent is water or an organic solvent composition for oral use.
상기 유기용매는 C1 내지 C4의 저급 알코올, 아세톤 및 이의 수용액으로 이루어진 군으로부터 선택되는 구강용 조성물.The method according to claim 3,
The organic solvent is a composition for oral cavity selected from the group consisting of C 1 to C 4 lower alcohol, acetone and an aqueous solution thereof.
상기 유기용매는 에탄올 또는 에탄올 수용액인 구강용 조성물.The method of claim 4,
The organic solvent is an oral composition of ethanol or ethanol aqueous solution.
상기 통초 추출물은 통초 수추출물에 분획화 유기용매를 가하여 추출한 분획물인 구강용 조성물.The method according to claim 1,
The tongcho extract is a composition for oral cavity which is a fraction extracted by adding a fractionated organic solvent to the water extract of Tongcho.
상기 분획화 유기용매는 에틸아세테이트 또는 부탄올인 구강용 조성물.The method of claim 6,
The fractionated organic solvent is ethyl acetate or butanol composition.
상기 구강용 조성물 총 중량에 대하여 상기 통초 추출물을 0.01 내지 50 중량%로 포함하는 것을 특징으로 하는 구강용 조성물.The method according to claim 1,
The composition for oral cavity, characterized in that containing the Tongcho extract 0.01 to 50% by weight based on the total weight of the composition for oral cavity.
상기 구강용 조성물은 치약, 구강청정제 및 구강용 스프레이드로 이루어진 군으로부터 선택되는 구강용 조성물.The method according to any one of claims 1 to 8,
The oral composition is selected from the group consisting of toothpaste, mouthwash and mouth spray.
상기 건강식품은 식품 또는 음료의 형태인 건강식품.The method of claim 10,
The health food is a health food in the form of food or drink.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110051654A KR20120133134A (en) | 2011-05-30 | 2011-05-30 | Composition for Prevention or Treatment of Dental Caries Comprising Extract of Tetrapanax papyriferus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110051654A KR20120133134A (en) | 2011-05-30 | 2011-05-30 | Composition for Prevention or Treatment of Dental Caries Comprising Extract of Tetrapanax papyriferus |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20120133134A true KR20120133134A (en) | 2012-12-10 |
Family
ID=47516557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110051654A KR20120133134A (en) | 2011-05-30 | 2011-05-30 | Composition for Prevention or Treatment of Dental Caries Comprising Extract of Tetrapanax papyriferus |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20120133134A (en) |
-
2011
- 2011-05-30 KR KR1020110051654A patent/KR20120133134A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101841181B1 (en) | Toothpaste composition comprising herval extract | |
KR100835899B1 (en) | Composition comprising zingiber officinale roscoe or gingerol isolated from the same for preventing or treating periodontitis | |
CN106535911B (en) | Oral composition for preventing and treating periodontitis containing cortex Mori extract and Euonymus Alata Sieb extract as active ingredients | |
KR101046621B1 (en) | Antimicrobial composition comprising sun-dried salt and koji mulberry extract | |
KR101450098B1 (en) | Composition for cleaning oral cavity containing fucoidan | |
KR102408893B1 (en) | Composition for prevention or treatment of oral disease comprising Pueraria Extract | |
KR20120133135A (en) | Composition for Prevention or Treatment of Dental Caries Comprising Extract of Cannabis sativa | |
KR20170141053A (en) | Composition for prevention or treatment of dental disease comprising an extract of Gardenia jasminoides | |
CN107073061B (en) | Oral composition for preventing and treating dental caries comprising cortex Mori extract and Euonymus Alata Sieb extract as active ingredients | |
KR20170141034A (en) | Composition for prevention or treatment of dental disease comprising Panax ginseng extract | |
WO2022075481A1 (en) | Oral care composition comprising sweet potato-derived potato syrup or potato syrup supernatant | |
KR102594674B1 (en) | Oral composition comprising herbal complex | |
KR102553374B1 (en) | Composition for prevention or treatment of dental disease comprising cistanoside A | |
KR20180118994A (en) | Composition for preventing or alleviating or treating dental caries or periodontal disease by growth of oral pathogen | |
KR100530578B1 (en) | Pharmaceutical composition comprising chitosan, chitosanoligosacchar ide and an extract of grapefruit seed having antimicrobial activity | |
KR102632336B1 (en) | Composition for prevention or treatment of dental disease comprising an extract of Daphne genkwa | |
KR20170141027A (en) | Composition for prevention or treatment of dental disease comprising an extract of Astragalus membranaceus | |
KR101280868B1 (en) | Pharmaceutical and food composition for preventing or treating cavity and periodontal disease comprising extract of Yacon as effective component | |
KR102132873B1 (en) | Composition for the prevention or treating of oral diseases comprising extract of indigo, Lindera Root, Madder Root and Psoraleae Semen | |
KR20120133134A (en) | Composition for Prevention or Treatment of Dental Caries Comprising Extract of Tetrapanax papyriferus | |
KR101544939B1 (en) | Composition for Prevention or Treatment of Dental Caries Comprising Extract of Gentianae macrophyllae Radix | |
KR101630829B1 (en) | Composition for preventing or treating oral disease comprising Echinacoside | |
KR102632335B1 (en) | Composition for prevention or treatment of dental disease comprising anemarrhena extract | |
KR102631909B1 (en) | Composition for prevention or treatment of dental disease comprising hydroxygenkwanin | |
KR102642552B1 (en) | Composition for prevention or treatment of dental disease comprising gardenoside |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |